Arrowhead Research Stock News

Antisense & RNAi Therapeutics Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)s traded shares stood at 0.5 million during the last session, with the companys beta value hitting 1.29. At the close of trading, the stocks price was $70.07, to imply a decrease of -1.07% or -$0.76 in intraday trading. The ARWR shares 52-week high remains $93.66, putting it -33.67% down since that Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR): How Can A Stock Be Down -8.68% Year To Date, But Still Loser Read More »

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Research analysts at Cantor Fitzgerald upped their FY2022 earnings per share estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, December 7th. Cantor Fitzgerald analyst A. Young now anticipates that the biotechnology company will earn $0.87 per share for the year, up from their previous forecast of $0.04. Arrowhead []

Thrivent Financial for Lutherans reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 61.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,359 shares of the biotechnology companys stock after selling 67,075 shares during the quarter. Thrivent Financial []

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock analysts at Zacks Investment Research issued their Q3 2022 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Monday, December 6th. Zacks Investment Research analyst D. Bautz expects that the biotechnology company will earn ($0.29) per share for the quarter. Zacks Investment Research also issued []

Nisa Investment Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 14.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,904 shares of the biotechnology companys stock after buying an additional 1,246 shares during the period. Nisa []

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 4th Annual Evercore ISI HealthCONx Conference December 2, 2021, 1:00 p.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation 18th Global Cardiovascular Clinical Trialists Forum December 3, 2021

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Equities researchers at B. Riley issued their Q1 2022 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, November 24th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter. B. Riley also []

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price lifted by SVB Leerink from $44.00 to $45.00 in a report issued on Tuesday, Price Targets.com reports. The brokerage currently has a market perform rating on the biotechnology companys stock. SVB Leerink also issued estimates for Arrowhead Pharmaceuticals FY2022 earnings at $3.12 EPS. Several other equities analysts have [] The post SVB Leerink Raises Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $45.00 appeared first on ETF Daily News .

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 4.44% to the previous days close as strong demand from buyers drove the stock to $74.04. Actively observing the price movement in the last trading, the stock closed the session at $70.89, falling within a range of $68.90 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Stock Price Forecast: $100 Read More »

Arrowhead Pharmaceuticals (NASDAQ:ARWR) released its quarterly earnings data on Monday. The biotechnology company reported ($0.61) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter in the []

Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its earnings results on Monday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter last year, []

Arrowhead Pharmaceuticals (NASDAQ:ARWR) released its quarterly earnings data on Monday. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same […]

The GSK share price is unmoved even as the company closes a $1billion deal with arrowhead to develop and market ARO-HSD.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective boosted by equities research analysts at SVB Leerink from $44.00 to $45.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. SVB Leerink’s target price points to a potential downside of […]